← Company intelligence

Robot maker · early

AcuSurgical

Corporate marketmedicalCurated record

Luca bedside robotic system for vitreoretinal microsurgery; provides motion scaling, tremor filtering, and physiological motion cancellation achieving sub-10-micron end-effector precision; targets intravitreal injections, vitrectomy, and epiretinal membrane peeling procedures.

HeadquartersMontpellier, FR
Founded2020
Corporate funding$7M
Team11-50
Deployments1
Open roles0
01

Company overview

Identity and operating footprint

Company typeRobot maker
Market segmentCorporate
StageSeries A
FoundersChristophe Spuhler (CEO), Philippe Poignet, Yassine Haddab, Philippe Gain, Gilles Thuret
Regions servedEurope
Countries deployedNot listed
Service footprintR&D in Montpellier, France (LIRMM/University of Montpellier spin-off); first-in-human trial at Ghent University Hospital, Belgium (July 2024); pivotal study planned for 2026.
Last reviewed2026-07-05
MX

Robot models

Specifications remain vendor-claimed

Machinemedical

Luca

  • End-effector precision up to 10 microns (vs ~100 microns achievable by human surgeons unaided)

    vendor-stated positioning precision of the Luca robotic system for retinal microsurgery

    Claim source
DP

Deployment log

Announced and cited only

AnnouncedCustomerSiteCountryCountEvidence
2024-07-01Ghent University Hospital (first-in-human clinical study)hospital, clinical trialBE1Announcement
CA

Funding history

Publicly announced rounds

Investors on recordMerieux Equity PartnersSupernova InvestSofimac InnovationIRDI Capital Investissement
TL

Company timeline

Milestones and announcements

2024-07-01Completed first-in-human clinical study with Luca at Ghent University Hospital (7 patients, all surgeries successful); confirmed safety and feasibilitySurgical Robotics Technology
2021-02-17Raised EUR 5.75M Series A led by Merieux Equity Partners and Supernova InvestBusinessWire
SC

Source ledger

3 unique public sources